- Molecular NameTopiramate
- SynonymTipiramate [French]; Tipiramato [Spanish]; topiramate tablet; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; Topiramic acid
- Weight339.365
- Drugbank_IDDB00273
- ACS_NO97240-79-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.37
- pkaN/A
- LogD (pH=7, predicted)0.36
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.02
- LogSw (predicted, AB/LogsW2.0)4.81
- Sw (mg/ml) (predicted, ACD/Labs)0.03
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds3
- TPSA123.92
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticonvulsant drug
- Absorption_value86.0
- Absorption (description)Rapid with pleak plasma concentrations occurring after 2 hours and a bioavailability of 80%.
- Caco_2N/A
- Bioavailability70.0
- Protein binding15.0
- Volume of distribution (VD)0.6~0.8 L/kg. In women it is approximately half of that in men although this difference is not considered clinically significant.
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNot extensively metabolized, 70% of the dose is eliminated unchanged in the urine. The other 30% is metabolized hepatically to six metabolites (formed by hydroxylation, hydrolysis, and glucuronidation), none of which constitute more than 5% of an administered dose.
- Half life19~23 h
- Excretion70% renal (in urine) in unchanged form
- Urinary Excretion70~97
- Clerance0.31~0.51 ml/min/kg
- ToxicitySymptoms of overdose include abdominal pain, agitation, blurred vision, convulsions, depression, dizziness, double vision, drowsiness, impaired coordination, impaired mental activity, low blood pressure, reduced consciousness, severe diarrhea, sluggishness, and speech problems.
- LD50 (rat)N/A
- LD50 (mouse)N/A